Stock Scorecard



Stock Summary for Aprea Therapeutics Inc (APRE) - $6.69 as of 3/28/2024 5:44:23 PM EST

Total Score

13 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for APRE

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for APRE

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for APRE

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for APRE

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for APRE

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update 3/26/2024 11:45:00 AM
Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million 3/14/2024 11:48:00 AM
Why Is Aprea Therapeutics Stock Trading Higher On Monday? - Aprea Therapeutics ( NASDAQ:APRE ) 3/11/2024 1:39:00 PM
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers 3/11/2024 12:29:00 PM
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024 3/5/2024 9:45:00 PM
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024 - Aprea Therapeutics ( NASDAQ:APRE ) 3/5/2024 9:45:00 PM
Smart Immune appoints key new members to its Board of Directors 2/16/2024 7:00:00 AM
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor 2/6/2024 1:01:00 PM
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024 - Aprea Therapeutics ( NASDAQ:APRE ) 1/4/2024 9:05:00 PM
VistaGen Therapeutics' Robust Financial Position and Promising Pipeline Underpin Buy Rating: A Comprehensive Analysis 11/12/2023 9:16:00 AM

Financial Details for APRE

Company Overview

Ticker APRE
Company Name Aprea Therapeutics Inc
Country USA
Description Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor protein. The company is headquartered in Boston, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2023
Next Earnings Date 5/13/2024

Stock Price History

Last Day Price 6.69
Last Day Price Updated 3/28/2024 5:44:23 PM EST
Last Day Volume 28,419
Average Daily Volume 55,083
52-Week High 8.85
52-Week Low 2.78
Last Price to 52 Week Low 140.65%

Valuation Measures

Trailing PE 0.49
Industry PE 103.22
Sector PE 62.25
5-Year Average PE -0.35
Free Cash Flow Ratio 1.16
Industry Free Cash Flow Ratio 12.71
Sector Free Cash Flow Ratio 31.21
Current Ratio Most Recent Quarter 5.14
Total Cash Per Share 5.78
Book Value Per Share Most Recent Quarter 4.54
Price to Book Ratio 1.12
Industry Price to Book Ratio 5.60
Sector Price to Book Ratio 21.72
Price to Sales Ratio Twelve Trailing Months 39.94
Industry Price to Sales Ratio Twelve Trailing Months 14.00
Sector Price to Sales Ratio Twelve Trailing Months 8.86

Share Statistics

Total Shares Outstanding 3,736,700
Market Capitalization 24,998,523
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 87.32%
Reported EPS 12 Trailing Months 12.31
Reported EPS Past Year -3.99
Reported EPS Prior Year -30.12
Net Income Twelve Trailing Months -14,286,756
Net Income Past Year -14,286,756
Net Income Prior Year -112,662,027
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth -19.99%

Balance Sheet

Total Cash Most Recent Quarter 21,600,000
Total Cash Past Year 21,600,000
Total Cash Prior Year 28,786,647
Net Cash Position Most Recent Quarter 21,600,000
Net Cash Position Past Year 21,600,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 16,953,506
Total Stockholder Equity Prior Year 25,643,678
Total Stockholder Equity Most Recent Quarter 16,953,506

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.14
MACD Signal -0.02
20-Day Bollinger Lower Band 2.78
20-Day Bollinger Middle Band 5.37
20-Day Bollinger Upper Band 7.96
Beta 0.17
RSI 44.71
50-Day SMA 4.42
200-Day SMA 7.09

System

Modified 3/28/2024 5:44:23 PM EST